Group 1 - The fentanyl concept index declined by 0.88%, ranking among the top declines in the concept sector as of July 29 [1] - Within the fentanyl sector, companies such as Botao Bio, Enhua Pharmaceutical, and Wanfu Bio experienced significant declines, while three companies, including China National Pharmaceutical Modern, Lingrui Pharmaceutical, and Renfu Pharmaceutical, saw slight increases of 1.07%, 0.17%, and 0.09% respectively [1] Group 2 - The fentanyl concept sector experienced a net outflow of 80 million yuan in capital today, with six stocks seeing net outflows, and five stocks with outflows exceeding 10 million yuan [2] - Renfu Pharmaceutical had the highest net outflow of 18.1651 million yuan, followed by Dongfang Bio, Enhua Pharmaceutical, and Wanfu Bio with net outflows of 16.8542 million yuan, 16.6752 million yuan, and 15.9620 million yuan respectively [2] - The top net inflow stocks in the fentanyl concept sector included China National Pharmaceutical Modern and China National Pharmaceutical, with net inflows of 9.5225 million yuan and 1.2608 million yuan respectively [2]

上海现代制药股份有限公司 关于下属子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）下属子公司国药集团容 生制药有限公司（以下简称国药容生）、国药一心制药有限公司（以下简称国药 一心）分别收到国家药品监督管理局核准签发的《药品注册证书》。现将相关情 况公告如下： 一、盐酸咪达普利片 （一）药品基本信息 药品名称：盐酸咪达普利片 剂型：片剂 规格：5mg 证券代码：600420 证券简称：国药现代 公告编号：2025-058 注册分类：化学药品 4 类 证书编号：2025S02225 （二）药品研发及市场情况 药品批准文号：国药准字 H20254897 上市许可持有人：国药集团容生制药有限公司 药品生产企业：国药集团容生制药有限公司 申请事项：药品注册（境内生产） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 盐酸咪达普利片适用于治疗：1、原发性高血压；2、肾实质性病变所致继发 性 ...

国药现代（600420）公告，下属子公司国药集团容生制药有限公司和国药一心制药有限公司分别收到国 家药品监督管理局核准签发的《药品注册证书》。其中，国药容生的药品名称为盐酸咪达普利片，剂型 为片剂，规格为5mg，注册分类为化学药品4类，证书编号为2025S02225，药品批准文号为国药准字 H20254897。国药一心的药品名称为亚叶酸钙注射液，剂型为注射剂，规格为10ml:0.1g(按C H N O 计)，注册分类为化学药品4类，证书编号为2025S02226，药品批准文号为国药准字H20254898。 ...

Group 1 - The event showcased four Shandong enterprises as examples of transitioning from a "manufacturing province" to a "brand strong province" [1][3] - The companies emphasized "chain development" to enhance industrial competitiveness, with Furuida Bio focusing on a full industry chain in the beauty sector, holding over 170 patents and participating in over 30 national standards [3][4] - Hisense Group is expanding from home appliances to high-end industries like semiconductors and smart energy, planning to drive investment or expansion in 25 related enterprises by 2024 [3][4] Group 2 - Furuida Bio aims to create a dual beauty ecosystem through its brand matrix, with a planned output value of 5 billion yuan for its innovation park in 2024 [4] - Hisense is innovating for overseas markets, exemplified by a custom black mirror refrigerator for South Africa, and has maintained the second position in global TV shipments for three consecutive years [4] - Shandong has cultivated 427 brands through systematic initiatives, with 80% of major technology projects in 2024 being undertaken by enterprises in collaboration with universities [4]

Policy Developments - The National Medical Products Administration (NMPA) has released a draft for public consultation regarding the adjustment of medical device classifications, aiming to optimize the registration and filing requirements for medical devices [1] Drug Approval - Yuyuan Pharmaceutical's YKYY029 injection has received clinical trial approval for treating hypertension, marking a significant step in the development of a novel siRNA drug [2] - Hengrui Medicine has received clinical trial approvals for four drugs, including SHR-8068 injection and Abediterib injection, with total R&D investments amounting to approximately 20.33 million yuan [3] Financial Reports - Microchip Biotech expects a net profit of 30.06 million yuan for the first half of 2025, driven by increased sales from new drug listings and optimized sales strategies [4] - China National Pharmaceutical Modern reported a 6.46% decline in net profit for the first half of the year, attributed to decreased sales and prices of certain antibiotics and other products [5] Capital Market - Tigermed announced the sale of its stake in Lixin Pharmaceutical for approximately 34.11 million USD, reflecting a strategic move in the context of the domestic pharmaceutical industry's consolidation [6] Industry Events - A breakthrough in brain-computer interface technology has been achieved in Shanghai, allowing patients with speech impairments to communicate through decoded brain activity [8] - Yuan Da Pharmaceutical's innovative nasal spray for dry eye treatment has received approval and its first prescriptions have been issued, providing a new treatment option for patients [9] Debt Resolution - Kangmei Pharmaceutical has reached a settlement agreement to resolve historical debt issues for 43.5 million yuan, facilitating the closure of related legal matters [10] Market Sentiment - Weier Pharmaceutical announced plans for its employee stock ownership platform to reduce its holdings by up to 1% of the company's shares, driven by shareholder funding needs [11]

Financial Performance Summary - In the first half of 2025, the company achieved operating revenue of 487,767.35 million RMB, a decrease of 18.16% compared to the same period last year [4] - The net profit attributable to shareholders of the listed company was 67,206.69 million RMB, down 6.46% year-on-year [4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 63,746.03 million RMB, a decline of 6.72% compared to the previous year [4] Business Operations Analysis - The decline in revenue was influenced by market supply and demand, with lower sales and prices for certain penicillin raw materials and intermediates [4] - The formulation business faced challenges, with sales revenue for some cephalosporins, hormone products, and neurological products decreasing due to centralized drug procurement and reduced terminal demand [4] - The company is focusing on strategic layout, actively promoting research and development, and enhancing market penetration while effectively reducing costs and expenses, which has stabilized profit margins [4]

Financial Performance Summary - The total operating revenue for the first half of 2025 was approximately 4.88 billion RMB, a decrease of 18.16% compared to the same period last year [2] - Operating profit decreased by 16.10% to approximately 920.16 million RMB [2] - Total profit decreased by 14.86% to approximately 924.93 million RMB [2] - Net profit attributable to shareholders was approximately 672.07 million RMB, down 6.46% year-on-year [2] - Basic earnings per share decreased by 6.46% to 0.5011 RMB per share [2] - The weighted average return on equity decreased by 0.68 percentage points to 4.96% [2] Asset and Equity Overview - Total assets at the end of the reporting period were approximately 19.66 billion RMB, a decrease of 1.49% from the beginning of the period [2] - The company's equity attributable to shareholders remained stable with a share capital of approximately 1.34 billion RMB [2] Operational Challenges and Strategic Response - The decline in net profit was attributed to lower sales and prices of certain penicillin raw materials and intermediates due to market supply and demand factors [3] - The formulation business faced revenue declines due to centralized drug procurement and reduced terminal demand for certain products [3] - In response to competitive pressures, the company is focusing on strategic layout, enhancing research and development, and reducing costs while stabilizing profit margins [3]

[Key Financial Data and Indicators](index=1&type=section&id=%E4%B8%80%E3%80%812025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E6%8C%87%E6%A0%87) In the first half of 2025, the company's core financial indicators showed a downward trend, with total operating revenue decreasing by 18.16% and net profit attributable to shareholders declining by 6.46%, while shareholders' equity and net assets per share saw slight growth Key Financial Data and Indicators for the Current Reporting Period | Item | Current Reporting Period (RMB) | Prior Year Same Period (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 4,877,673,521.93 | 5,960,093,922.86 | -18.16 | | Operating Profit | 920,163,725.85 | 1,096,704,023.68 | -16.10 | | Total Profit | 924,926,954.05 | 1,086,401,902.24 | -14.86 | | Net Profit Attributable to Shareholders of Listed Company | 672,066,877.31 | 718,477,263.45 | -6.46 | | Basic Earnings Per Share (RMB/share) | 0.5011 | 0.5357 | -6.46 | Key Financial Data and Indicators at the End of the Current Reporting Period | Item | End of Current Reporting Period (RMB) | Beginning of Current Reporting Period (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 19,658,833,692.75 | 19,955,597,470.69 | -1.49 | | Shareholders' Equity Attributable to Shareholders of Listed Company | 13,643,330,466.99 | 13,203,924,172.51 | 3.33 | | Net Assets Per Share (RMB/share) | 10.17 | 9.85 | 3.25 | [Explanation of Operating Performance and Financial Condition](index=1&type=section&id=%E4%BA%8C%E3%80%81%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) During the reporting period, the company experienced declines in both revenue and profit, primarily due to market supply-demand shifts affecting penicillin-related raw materials and intermediates, alongside reduced sales of certain preparations due to centralized drug procurement and decreased demand, yet managed to stabilize profitability through strategic focus, R&D, and cost control - Sales volume and prices of certain penicillin-related raw materials and intermediates **decreased year-on-year** due to market supply and demand fluctuations[7](index=7&type=chunk) - Sales revenue for certain cephalosporin, hormone, and neurological products in the preparation business **declined year-on-year** due to centralized drug procurement and reduced end-user demand[7](index=7&type=chunk) - The company **significantly reduced period expenses and stabilized its profit margin** through strategic focus, R&D advancement, market penetration, and cost reduction initiatives[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=%E4%B8%89%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company explicitly states that the financial data in this performance express report are preliminary and unaudited, potentially differing from the final audited data in the semi-annual report, cautioning investors about associated investment risks - The key financial data for the first half of 2025 contained in this announcement are **preliminary and unaudited by an accounting firm**[2](index=2&type=chunk)[8](index=8&type=chunk) - The final specific data will be subject to the company's 2025 semi-annual report, and investors are advised to be **aware of investment risks**[8](index=8&type=chunk)

Group 1 - The animal vaccine sector saw a rise of 2.91%, leading the concept sectors in growth, with 16 stocks increasing in value, including BioShares which hit the daily limit, and others like Kexing Pharmaceutical and Ruipu Bio rising by 7.15%, 5.65%, and 3.56% respectively [1] - The main inflow of funds into the animal vaccine sector was 281 million yuan, with 10 stocks receiving net inflows, and 6 stocks seeing inflows exceeding 10 million yuan, led by BioShares with a net inflow of 159 million yuan [1] - The top stocks by net inflow included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Ruipu Bio, with net inflows of 53.91 million yuan, 52.39 million yuan, and 28.10 million yuan respectively [1] Group 2 - In terms of fund inflow ratios, BioShares, Kexing Pharmaceutical, and Luoniushan had the highest net inflow rates at 19.39%, 9.63%, and 8.85% respectively [2] - The animal vaccine concept fund inflow rankings showed BioShares with a daily increase of 10.04% and a turnover rate of 8.74%, while Haizheng Pharmaceutical and Kexing Pharmaceutical followed with increases of 2.71% and 7.15% respectively [2] - Other notable stocks included Ruipu Bio with a 5.65% increase and a turnover rate of 9.16%, and Luoniushan with a 3.49% increase and a turnover rate of 4.43% [2]

证券代码：600420 证券简称：国药现代 公告编号：2025-056 上海现代制药股份有限公司 2024年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.20元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | A 股 | 2025/7/17 | － | 2025/7/18 | 2025/7/18 | 差异化分红送转：否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 26 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称中国结算上海分公司）登记在册的公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本1,341,172,692股为基数， ...